Rein Therapeutics Inc (RNTX)

May 27, 2025, 7:00 AM EDT - 10 days ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

May 19, 2025, 4:51 PM EDT - 17 days ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 15, 2025, 4:09 PM EDT - 21 days ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 25 days ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 5 weeks ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Apr 30, 2025, 4:05 PM EDT - 5 weeks ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 28, 2025, 7:00 AM EDT - 5 weeks ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 23, 2025, 7:00 AM EDT - 6 weeks ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 15, 2025, 7:00 AM EDT - 7 weeks ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 7, 2025, 4:17 PM EDT - 2 months ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update